The development of anticancer MDR in breast cancer could be attributed to ABC transporters, overexpression of the P-glycoprotein (P-gp), MDR associated protein (MRP1), breast cancer resistance protein (BCRP), microtubules alteration, altered enzymes, p-53 tumor suppressor gene are the other significant challenges in breast cancer therapy [12,19,20]. This evidence concerns the gene PGP and breast cancer.